[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572572":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":87,"collaborators":89,"id":96,"slug":10,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":10,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":10,"enrollmentInfo":104,"targetDuration":10,"studyType":107,"phases":10,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"University of Minnesota","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with ALS",null,"Adults with early stage ALS",[13,14],"Diagnostic Test: Magnetic Resonance Imaging","Diagnostic Test: Plasma neurofilament light chain (NfL) quantification",{"label":16,"type":10,"description":17,"interventionNames":18},"Participants without ALS","Control participants free from neurological disease",[13,14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DIAGNOSTIC_TEST","Magnetic Resonance Imaging","Participants will undergo 3T MRI scanning of the brain and cervical spine MRIs",[9,16],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Plasma neurofilament light chain (NfL) quantification","Participants will undergo a blood draw for the quantification of plasma neurofilament light chain",[9,16],[30],{"name":31,"affiliation":5,"role":32},"Pramod Pisharady, PhD","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Melisa Bailey, MS","CONTACT","612-624-4911","baile807@umn.edu",[40,59,74],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"University of Florida","RECRUITING","Gainesville","Florida","32608","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-82.32483,29.65163,{"lat":52,"lon":51},[55,57],{"name":56,"role":36,"phone":10,"phoneExt":10,"email":10},"Jennifer Steshyn, MABMH, CCRP",{"name":58,"role":32,"phone":10,"phoneExt":10,"email":10},"James Wymer, MD, FAAN",{"facility":60,"status":42,"city":61,"state":62,"zip":63,"country":46,"countryCode":47,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Northwestern University","Evanston","Illinois","60208",{"type":49,"coordinates":65},[66,67],-87.69006,42.04114,{"lat":67,"lon":66},[70,72],{"name":71,"role":36,"phone":10,"phoneExt":10,"email":10},"Emma Schmidt",{"name":73,"role":32,"phone":10,"phoneExt":10,"email":10},"Senda Ajroud-Driss, MD",{"facility":5,"status":42,"city":75,"state":76,"zip":77,"country":46,"countryCode":47,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Minneapolis","Minnesota","55455",{"type":49,"coordinates":79},[80,81],-93.26384,44.97997,{"lat":81,"lon":80},[84,85],{"name":35,"role":36,"phone":10,"phoneExt":10,"email":38},{"name":86,"role":32,"phone":10,"phoneExt":10,"email":10},"David Walk, MD",{"type":88,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[90,93],{"name":91,"class":92},"Food and Drug Administration (FDA)","FED",{"name":94,"class":95},"Minnesota Office of Higher Education","OTHER_GOV","100572572",false,"NCT06735014","Multicenter ALS Imaging Study","Multicenter Longitudinal Imaging in ALS for Disease Biomarker Development","For participants with ALS:\n\n* \\\u003C 36 months since onset of symptoms\n* Definite, probable, lab supported-probable or possible ALS by El Escorial criteria OR definite, probable or possible ALS per Awaji-Shima Criteria\n* Forced vital capacity within the last 90 days ≥ 60% of the predicted value\n* Able to consent for themselves\n* Able to read and speak English\n* Clear of any contraindications for MRI\n\nExclusion Criteria:\n\n* Individuals will be excluded if they have any condition that makes MRI unsafe or if they are unable to comply with instructions.\n* All participants will undergo a neurologic examination at enrollment. Control participants with clinically significant abnormal findings on neurological examination will be excluded from the study.","ALL","18 Years",{"count":105,"type":106},90,"ESTIMATED","OBSERVATIONAL","This is a multi-site study of ALS participants and healthy controls who will undergo brain and cervical spine MRIs and NfL blood testing at up-to 4 time points over the course of a year. The primary goal is to identify objective biomarkers of disease progression that are biologically relevant, linearly progressive, and sensitive to change.",[110,111],"Amyotrophic Lateral Sclerosis","ALS",[22,113,114,115,116,117],"MRI","ALSFRS-R","ECAS","plasma neurofilament light","NfL","2026-05-07",{"date":120,"type":121},"2026-05-12","ACTUAL",{"date":123,"type":121},"2024-09-15",{"date":125,"type":106},"2028-08-31",{"name":5,"class":6},3]